

**UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF NEW YORK**

-----X

In re: OXYCONTIN ANTITRUST LITIGATION

-----X

PURDUE PHARMA L.P., et al.,  
Plaintiffs,

-against-

TEVA PHARMACEUTICALS, USA, INC.,  
Defendant.

-----X

USDC SDNY  
DOCUMENT  
ELECTRONICALLY FILED  
DOC #:  
DATE FILED: 1/22/14

04 **MD** 1603 (SHS)

This document relates to:

11 **CIVIL** 2037 (SHS)

12 **CIVIL** 5083 (SHS)

**JUDGMENT**

Whereas this Court having held a consolidated bench trial concerning six patents associated with the pain reliever OxyContin, and the matter having come before the Honorable Sidney H. Stein, United States District Judge, and the Court, on January 14, 2014, having rendered its Findings of Fact and Conclusions of Law ordering the following: 1. Each of plaintiffs' requests for relief is denied; 2. The following declaratory judgments shall enter in favor of Teva and against plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes Technologies, and Grunenthal GmbH: a. Claims 3 and 19 of U.S. Patent No. 7,674,799 are invalid; b. Claims 30-34 and 76-79 of U.S. Patent No. 7,674,800 are invalid; c. Claims 1, 4, and 5 of U.S. Patent No. 7,683,072 are invalid; d. Teva's proposed products do not infringe claims 1, 2, 6, and 9 of U.S. Patent No. 7,776,314; 3. A further declaratory judgment shall be entered, in favor of Teva and against plaintiffs Purdue Pharma L.P. and Grunenthal GmbH, that claims 1, 2, 5, 7, and 8 of U.S. Patent No. 8,114,383 are invalid; and 4. No attorneys fees will be awarded, because the prevailing party, Teva, has not demonstrated that this is an exceptional case, it is,

**ORDERED, ADJUDGED AND DECREED:** That for the reasons stated in the

Court's Findings of Fact and Conclusions of Law, the Court Orders as follows:

1. Each of plaintiffs' requests for relief is denied.

2. The following declaratory judgments is entered in favor of Teva and against plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes Technologies, and Grunenthal GmbH:

a. Claims 3 and 19 of U.S. Patent No. 7,674,799 are invalid.

b. Claims 30-34 and 76-79 of U.S. Patent No. 7,674,800 are invalid.

c. Claims 1, 4, and 5 of U.S. Patent No. 7,683,072 are invalid.

d. Teva's proposed products do not infringe claims 1, 2, 6, and 9 of U.S. Patent No. 7,776,314.

3. A further declaratory judgment is entered, in favor of Teva and against plaintiffs Purdue Pharma L.P. and Grunenthal GmbH, that claims 1, 2, 5, 7, and 8 of U.S. Patent No. 8,114,383 are invalid.


4. No attorneys fees will be awarded, because the prevailing party, Teva, has not demonstrated that this is an exceptional case.

**Dated:** New York, New York  
January 22, 2014

**RUBY J. KRAJICK**

\_\_\_\_\_  
**Clerk of Court**

**BY:**

  
\_\_\_\_\_  
**Deputy Clerk**

**THIS DOCUMENT WAS ENTERED  
ON THE DOCKET ON \_\_\_\_\_**